Last reviewed · How we verify
Docetaxel monotherapy (docetaxel-monotherapy)
Docetaxel binds to tubulin, stabilizing microtubules and preventing their depolymerization, leading to cell cycle arrest and apoptosis in cancer cells.
At a glance
| Generic name | docetaxel-monotherapy |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 3 |
| Annual revenue | 798 |
Mechanism of action
Docetaxel works by binding to a protein called tubulin, which is essential for cell division. By stabilizing the structures made from tubulin (microtubules), docetaxel prevents cancer cells from dividing and causes them to die.
Approved indications
Common side effects
- Nausea
- Diarrhoea
- Decreased appetite
- Anaemia
- Fatigue
- Asthenia
- Constipation
- Vomiting
- Weight decreased
- Neutrophil count decreased
- Stomatitis
- Hypertension
Key clinical trials
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) (PHASE1, PHASE2)
- ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer (PHASE3)
- A Phase III Study Evaluating YL201 Versus ICC in 2L ESCC (PHASE3)
- Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations (PHASE3)
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) (PHASE3)
- A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer (PHASE3)
- A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (PHASE3)
- Study of Novel Treatment Combinations in Patients With Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel monotherapy CI brief — competitive landscape report
- Docetaxel monotherapy updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI